Evidence map›Paper›PMID 33175889›Full record

ArticlePloS one2020

Repurposing a microfluidic formulation device for automated DNA construction.

Garima Goyal, Nick Elsbree, Michael Fero, Nathan J Hillson, Gregory Linshiz

Abstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. High-throughput structure determination of an intrinsically disordered protein using cell-free protein crystallization.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Garima GoyalTechnology Division, DOE Joint BioEnergy Institute, Emeryville, California, United States of America.ORCID 0000-0003-4886-8565
Nick ElsbreeTeselaGen Biotechnology, San Francisco, California, United States of America.
Michael FeroTeselaGen Biotechnology, San Francisco, California, United States of America.ORCID 0000-0002-4845-7048
Nathan J HillsonTechnology Division, DOE Joint BioEnergy Institute, Emeryville, California, United States of America.
Gregory LinshizTechnology Division, DOE Joint BioEnergy Institute, Emeryville, California, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microfluidic applications have expanded greatly over the past decade. For the most part, however, each microfluidics platform is developed with a specific task in mind, rather than as a general-purpose device with a wide-range of functionality. Here, we show how a microfluidic system, originally developed to investigate protein phase behavior, can be modified and repurposed for another application, namely DNA construction. We added new programable controllers to direct the flow of reagents across the chip. We designed the assembly of a combinatorial Golden Gate DNA library using TeselaGen DESIGN software and used the repurposed microfluidics platform to assemble the designed library from off-chip prepared DNA assembly pieces. Further experiments verified the sequences and function of the on-chip assembled DNA constructs.

Indexed as

Lab-On-A-Chip DevicesOligonucleotide Array Sequence AnalysisComputational BiologyDNAEscherichia coliMicrofluidicsPattern Recognition, AutomatedPolymerase Chain ReactionSoftwareDNA

Identifiers

PMID33175889
PMCPMC7657503

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.